H1N1

New frontier in fighting viruses: electromagnetic waves can render flu and COVID viruses inactive, with a success rate of over 90%. This is the “e4life” new smart prevention device.

Retrieved on: 
Wednesday, March 6, 2024
Biotechnology, Health, Medical Devices, Infectious Diseases, Consumer Electronics, Health Technology, Technology, Mobile, Wireless, Transfer, Nature, Celio, H1N1, Field line, Siesta Key (TV series), Multimedia, Research, Aerosol, Translation, Animal, Hospital, Radiation, Wi-Fi, Biomedicine, University, COVID-19, ELT, Virus, Business, Lendlease, Electricity, Plasma protein binding, Human, Environment, Viral load, Vaccine

This started with the COVID-19 pandemic and continues today, with such products now accounting for 11% of the market.

Key Points: 
  • This started with the COVID-19 pandemic and continues today, with such products now accounting for 11% of the market.
  • This technology, patented in Italy, uses no chemical agents or filters, but instead transmits electromagnetic waves to render the viral load in aerosols inactive.
  • The unique e4shield technology subjects viruses to a precise oscillating electromagnetic field that resonates with the outer shell until it breaks.
  • Continuous scientific research will enable the devices to expand the number of types of pathogens that they can render inactive.

Human medicines European public assessment report (EPAR): Flucelvax Tetra, influenza vaccine (surface antigen, inactivated, prepared in cell cultures), Date of authorisation: 12/12/2018, Revision: 15, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Tetra, Medical Subject Headings, Marketing, Protein, INN, Immune system, Risk, Fatigue, World, H3N2, Allergy, ATC, Pain, WHO, International, Vaccine, Headache, Disease, Ageing, Language, Influenza, Tenderness, Irritability, Influenza B virus, H1N1, European Medicines Agency, World Health Organization, Select, Patient, Bruise, Safety, Anatomy, IIA, Skin

Human medicines European public assessment report (EPAR): Flucelvax Tetra, influenza vaccine (surface antigen, inactivated, prepared in cell cultures), Date of authorisation: 12/12/2018, Revision: 15, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Flucelvax Tetra, influenza vaccine (surface antigen, inactivated, prepared in cell cultures), Date of authorisation: 12/12/2018, Revision: 15, Status: Authorised

PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 14, 2023
Well, Neck, Annual general meeting, DNA, Cervical cancer, Castration, ICI, PSA, ADC, Patient, Research, Lymph, E pluribus unum, Neoplasm, Cytokine, Cancer, Pembrolizumab, Oncology, Doctor of Philosophy, OS, Burtness, Webcast, Safety, Fourth grade, Food, Head, International, Radiation, PDS, Infection, Society, SOC, PDSB, KOL, Opinion, National Cancer Institute, IL12, Recurrence, CRT, CD8, Ferret, Nivolumab, Squamous-cell carcinoma, Biomarker, Standard works, HDAC, Clinical trial, NCI, FDA, Biotechnology, Vaccine, Prostate cancer, Immunotherapy, Survival, TH1, Prostate-specific antigen, Cetuximab, HPV, Docetaxel, Pharmaceutical industry, Medical imaging, Birth control, H1N1

The Company will provide a business update on its conference call and webcast at 8:00 AM EST today.

Key Points: 
  • The Company will provide a business update on its conference call and webcast at 8:00 AM EST today.
  • PDS Biotech anticipates initiation of VERSATILE-003 in Q1 2024.
  • PDS Biotech’s cash balance as of September 30, 2023 was approximately $54.3 million.
  • PDS Biotech believes that, with initiating the VERSATILE-003 Phase 3 clinical trial in the first quarter of 2024, its available cash resources will sustain operational and research and development endeavors into the third quarter of 2024.

Bioxytran Gets Broad Patent Coverage on 60+ Viruses

Retrieved on: 
Tuesday, October 24, 2023
RSV, Patent, Epstein–Barr virus, Viral, HAART, Reading, Lectin, Nipa, Hepatitis C, Measles, Protease, Pathology, HIV, Intellectual property, Virus, Cell, Research, Drug development, COVID-19, Mumps, MOA, Virology, Rubella, Simplex, Shingles, Drug resistance, Movement, Enzyme inhibitor, Plasma protein binding, DNA, Vaccine, Pharmaceutical industry, H1N1, Galectin

BOSTON, MASSACHUSETTS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral diseases, announced that the U.S Patent and Trademark Office (USPTO) has published the Company’s patent application WO2023178228A1 Lectin-binding carbohydrates for treating viral infections. The pending patent covers broad claims about the use of hundreds of combinations of antiviral complex carbohydrate drugs to treat over 60 named viruses.

Key Points: 
  • The pending patent covers broad claims about the use of hundreds of combinations of antiviral complex carbohydrate drugs to treat over 60 named viruses.
  • This patent represents what we believe is a new direction in the evolution of antiviral therapies that originally started during the HIV epidemic.
  • This pending patent with its broad claims also shows the Company is well-positioned with respect to its intellectual property portfolio.
  • This patent covers some of the largest indications in virology and includes viruses like COVID-19, influenza, herpes, Epstein-Barr, shingles, hepatitis C, measles, mumps, and rubella.

AirDoctor Unveils Next-Generation Smart Air Purifiers for Healthier Living

Retrieved on: 
Wednesday, October 25, 2023
Carbon, Air pollution, Ozone, Pollen, Temperature, SARS-CoV-2, Life, Humidity, Wi-Fi, Atmosphere, Engineering, Bacteria, HEPA, Formaldehyde, Mobile phone, Heating, ventilation, and air conditioning, H1N1

LOS ANGELES, Oct. 24, 2023 /PRNewswire/ -- AirDoctor announced its next generation of Wi-Fi connected air purifiers.

Key Points: 
  • LOS ANGELES, Oct. 24, 2023 /PRNewswire/ -- AirDoctor announced its next generation of Wi-Fi connected air purifiers.
  • Through a mobile app, users receive real-time air quality updates, filter replacement alerts, and the ability to control units from any location – ensuring consistent air quality and peace of mind.
  • "Our engineering team worked very hard to deliver a connected AirDoctor unit that provides useful and convenient features to our customers," said Peter Spiegel, CEO and founder of AirDoctor.
  • "We're giving people real-time info about their indoor and outdoor air quality, to help them live a healthier life.

Longhorn Vaccines and Diagnostics Presents Data Demonstrating Durability of LHNVD-105 Universal Influenza Vaccine in Animal Models at IDWeek 2023

Retrieved on: 
Monday, October 16, 2023
Veterinary, Health, Vaccine, Immunoglobulin G, Public, Antibody, ELISA, Immunity, Pig, Influenza B virus, Epitope, Peptide, Group 1, Infection, Influenza, Isotype, Diagnosis, MD, H1N1, Matrix

Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented new data from an animal study indicating the durability and broad strain coverage of LHNVD-105, the company’s universal influenza vaccine candidate.

Key Points: 
  • Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented new data from an animal study indicating the durability and broad strain coverage of LHNVD-105, the company’s universal influenza vaccine candidate.
  • The data was presented at IDWeek 2023, which took place in Boston from October 11-15, 2023.
  • Traditional seasonal influenza vaccines attempt to match circulating influenza strains.
  • Alternate vaccine strategies that target multiple key components of the virus that are conserved across influenza viruses have the potential to combat this issue.

PDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies

Retrieved on: 
Wednesday, September 20, 2023
Vaccine, Infection, National Institute of Allergy and Infectious Diseases, European Scientific Cooperative on Phytotherapy, Antigen, Cleveland Clinic, Human, Biotechnology, Vaccination, PDSB, Ferret, NG2, HAI, Weight loss, H3N2, Doctor of Philosophy, Mock, Protein, CD8, Animal, PDS, MD, CD4, Conference, COBRA, H1N1

“We are encouraged that PDS0202 has demonstrated activity in generating protective hemagglutination inhibition assay (HAI) antibody responses in pre-immune ferret studies, which are the gold standard in influenza vaccine testing.

Key Points: 
  • “We are encouraged that PDS0202 has demonstrated activity in generating protective hemagglutination inhibition assay (HAI) antibody responses in pre-immune ferret studies, which are the gold standard in influenza vaccine testing.
  • In addition to active neutralization of various influenza strains, the data demonstrated that PDS0202 prevented illness, weight loss and importantly protected the lungs of vaccinated animals from H1N1,” said Dr. Ross.
  • PDS0202 combines PDS Biotech’s Infectimune® novel investigational immune activating platform with proprietary Computationally Optimized Broadly Reactive Antigens (COBRA) influenza antigens.
  • This robust immune response to the COBRA antigens suggests strong potential for PDS0202 as a broad and long-term protecting universal influenza vaccine.

Bioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-M

Retrieved on: 
Thursday, September 14, 2023
SARS-CoV-2, COVID-19, Article, Mutation, Viral, COVID, Respiratory syncytial virus vaccine, RSV, Lower respiratory tract infection, Viral load, Virus, Complex, Vaccine, H1N1

ProLectin-M (“PL-M”) and ProLectin-I were the galectin antagonists used on these 3 viruses to produce the results set forth in the Article.

Key Points: 
  • ProLectin-M (“PL-M”) and ProLectin-I were the galectin antagonists used on these 3 viruses to produce the results set forth in the Article.
  • The in vitro data demonstrates that PL-M has the potential to be a broad-spectrum antiviral useful in the treatment of Upper Respiratory Infections (“URI”).
  • Additionally, the existing antiviral treatment options have seen the first signs of resistance calling into question their long-term viability.
  • PL-M is a next generation antiviral that is designed to prevent the virus from entering the cell.

I think I have the flu. Should I ask my GP for antivirals?

Retrieved on: 
Tuesday, August 29, 2023
Infection, COPD, Human, Obesity, Neuraminidase, SARS-CoV-2, Aborigine, Fever, Respiratory system, Immunity, Woman, Medicine, Research, COVID, Cell, Cough, Common, Down syndrome, Myalgia, Nose, Vomiting, Chronic obstructive pulmonary disease, Hospital, RSV, Patient, Risk, Immune system, RAT, Viral, Sneeze, Government, Ageing, Immunodeficiency, Headache, Death, Virus, Sore throat, PCR, Mouth, Fatigue, Disease, Pharmaceutical industry, Vaccine, Glass wool, Meat, Birth control, Toy, Poultry farming, Peramivir, Zanamivir, Oseltamivir, H1N1

If you test positive for COVID and you’re eligible for antivirals, you’ll likely ask your GP for a script to protect you from severe disease.

Key Points: 
  • If you test positive for COVID and you’re eligible for antivirals, you’ll likely ask your GP for a script to protect you from severe disease.
  • So when should you make the effort to see a GP for a prescription for influenza antivirals?

What exactly is influenza?


    The flu is primarily a viral infection of the respiratory system that can spread through sneezing, coughing, or touching contaminated objects then touching your nose or mouth. Common symptoms include headache, sore throat, fever, runny or blocked nose and body aches that last a week or more. Influenza is actually a group of viruses, divided into several sub-groups. Flu A and B are the most common groups that circulate in humans.

What are flu antivirals?

    • Most flu antivirals target neuraminidase, an important enzyme the virus uses to release itself from cells.
    • On the other hand, COVID antivirals work by inhibiting other parts of the viral life cycle involved in the virus replicating itself.
    • Read more:
      Should I get a flu vaccine this year?

How effective are antivirals for the flu?

    • Antivirals have the greatest effect if started 24-72 hours after symptoms.
    • In a study from the 2009 swine flu (H1N1) pandemic in the United States, treatment with antivirals (Tamiflu and Relenza) reduced the chance of needing to be hospitalised.
    • The research is less clear about whether antivirals prevent the development of flu complications such as secondary bacterial pneumonia.

Are flu antivirals becoming less effective?

    • The impact of the antiviral resistance is unclear but there is evidence indicating resistant strains can uphold their ability to replicate effectively and spread.
    • However, government agencies and surveillance programs are constantly monitoring the spread of antiviral resistance.

Antivirals can also prevent the flu if you’ve been exposed

    • Tamiflu and Relenza can also be used to prevent flu infections, if we’re exposed to the virus or come into contact with infected people.
    • Some studies suggest Tamiflu and Relenza can reduce the chance of developing symptomatic influenza by 70-90%.

So who should talk to their GP about a prescription?


    Australian guidelines recommend doctors offer antivirals to people with influenza who have severe disease or complications. Doctors can also consider treatment for people at higher risk of developing severe disease from influenza. This includes:
    • Antiviral treatment also can be considered for otherwise healthy symptomatic patients who have confirmed or suspected influenza, if they can start treatment within 48 hours of developing symptoms.
    • In some instances a doctors can make a clinical diagnosis of influenza based on the symptoms and known close flu positive contacts of the patient.
    • Read more:
      What happens in our body when we encounter and fight off a virus like the flu, SARS-CoV-2 or RSV?

Europe Air Purifiers Market Report 2023: New Air Purifier Launches Take the European Market by Storm - Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, August 4, 2023
Retail, Other Retail, Pressure, Electron, Allergy, Ultra-low particulate air, COPI, Atmosphere, Internet of things, Gas, NO2, Stroke, Coronavirus, Influenza A virus subtype H1N1, Lung cancer, Pollen, Molekule, Public interest, Science, Pollutant, Chronic obstructive pulmonary disease, HVAC, Market, Nitrogen dioxide, Streamer, Risk, AHU, Smoke, PM10, Particulates, Bluetooth, United Kingdom, City, HEPA, Filtration, Bacteria, PECO, MITES, Health, Growth, WHO, Air pollution, Allergen, Virus, Imperial College London, Pneumonia, Environment, World Health Organization, Vaccine, Environmental remediation, Daikin, H1N1

In the industrial setting, air purifiers can be utilized to clean the air before processing.

Key Points: 
  • In the industrial setting, air purifiers can be utilized to clean the air before processing.
  • Technology-based air purifiers are further influencing the growth of the air purifiers market in Europe.
  • Therefore, rising air pollution drives the market for air purifiers in Europe.
  • Company Profiles: Detailed analysis of the major companies present in Europe air purifiers market.